#77 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need this information to provide evidence-based counseling to pregnant patients about cannabis risks, including potential effects on fetal neurodevelopment and birth outcomes. Patients planning pregnancy or currently pregnant require clear guidance that no safe threshold exists for cannabis use, enabling them to make informed decisions about their health and their baby’s development. This guidance helps clinicians fulfill their duty to discuss teratogenic substances and establish appropriate prenatal care protocols.
Current evidence indicates that no amount of cannabis use is considered safe during pregnancy, as tetrahydrocannabinol (THC) crosses the placental barrier and may impair fetal neurodevelopment, increase risk of adverse birth outcomes, and potentially affect long-term cognitive and behavioral development in exposed children. Pregnant patients who use cannabis face additional risks including hyperemesis gravidarum, impaired placental function, and potential interactions with other medications, while the developing fetus may experience disrupted endocannabinoid signaling critical for brain maturation. Major medical organizations including the American College of Obstetricians and Gynecologists recommend against cannabis use in pregnancy and lactation due to insufficient safety data and documented neurotoxic effects in animal models and observational studies. Clinicians should screen all pregnant patients for cannabis use as part of routine prenatal care, provide evidence-based counseling about teratogenic risks, and consider referral to addiction services for patients unable to discontinue use. The practical implication for clinical practice is that pregnant patients and those planning conception should be explicitly counseled that cannabis use is contraindicated, and alternative symptom management strategies should be offered for conditions like nausea or anxiety commonly self-treated with cannabis.
“The evidence from human studies and clinical observation is clear and consistent: we advise pregnant patients to avoid cannabis entirely, as THM crosses the placenta and carries documented risks to fetal neurodevelopment and birth outcomes. This isn’t a gray area where we’re waiting for more data—the data we have supports a straightforward recommendation against use.”
🤰 While the evidence base regarding cannabis use in pregnancy continues to evolve, current clinical and public health guidance uniformly advises against any use during pregnancy due to concerns about fetal neurodevelopment, placental function, and adverse birth outcomes, though long-term epidemiologic data remain limited. Healthcare providers should recognize that pregnant patients or those planning pregnancy may be using cannabis for symptom management—particularly for nausea, anxiety, or chronic pain—creating a tension between symptom relief and fetal safety that requires compassionate, non-judgmental counseling. The landscape is complicated by variable state regulations, inconsistent product labeling and potency information, and growing normalization of cannabis use in some communities, all of which may influence patient perceptions of risk. Given these complexities, clinicians should routinely screen for cannabis use in pregnancy and preconception counseling using open-ended questions, discuss evidence-based alternatives for symptom management, and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
